In clinical settings, administration of TNF inhibitors can trigger the development of autoantibodies and even lupus manifestation (i.e., drug-induced lupus) in patients with rheumatoid arthritis and inflammatory bowel diseases [48,49]. Here, TNF is linked to inflammatory bowel disease.